Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: TBL 12 Clear all

Conditions: Myocardial Ischemia
Interventions: Dapagliflozin 10mg Tab, Placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Vitamin D Deficiency
Interventions: Redoxon VI, placebo; Dietary Supplement
Lead sponsor: Oregon State University; Other
Eligibility: 55 Years to 75 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Corvallis, Oregon

Conditions: Cystic Fibrosis
Interventions: VX-121, TEZ, VX-561, TEZ/IVA, IVA, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 12
States / cities: Los Angeles, California • Oakland, California • Lexington, Kentucky + 9 more

Conditions: Rheumatoid Arthritis
Interventions: Golimumab, Methotrexate, Placebo; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 20
States / cities: Peoria, Arizona • Aventura, Florida • Orlando, Florida + 17 more

Conditions: Impotence
Interventions: tadalafil, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 10
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Newport Beach, California + 7 more

Conditions: Chronic Stroke, Hemiparesis
Interventions: BCI Rehabilitation, Range of Motion Therapy; Device · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 85 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cirrhosis, Liver, Portal Hypertension
Interventions: Enhanced Usual Care, Lactulose, Investigator recommended exercise, TeleTai-Chi (virtual); Behavioral · Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Philadelphia, Pennsylvania • Dallas, Texas

Conditions: Primary Ovarian Insufficiency
Interventions: Hormone Replacement Therapy, Combined Oral Contraceptives; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 14 Years to 45 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Lymphoma, Chronic Myelomonocytic Leukemia
Interventions: Ascorbic Acid, Carboplatin, Cisplatin, Cytarabine, Dexamethasone, Etoposide, Gemcitabine Hydrochloride, Ifosfamide, Laboratory Biomarker Analysis, Oxaliplatin, Placebo Administration, Questionnaire Administration, Rituximab, Decitabine, Biospecimen Collection, Core Biopsy, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography, Positron Emission Tomography, Magnetic Resonance Imaging, Central Venous Cannula Insertion, Portacath Placement, Computed Tomography, Decitabine and Cedazuridine; Dietary Supplement · Drug · Other + 2 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2033
U.S. locations: 4
States / cities: Mankato, Minnesota • Rochester, Minnesota • Eau Claire, Wisconsin + 1 more

Conditions: Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated, Treatment-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Lymphoblastic Lymphoma, in Relapse, Lymphoblastic Lymphoma, Refractory, Acute Leukemia of Ambiguous Lineage in Relapse, Acute Leukemia of Ambiguous Lineage
Interventions: Venetoclax, Azacitidine, Cytarabine, Methotrexate, Hydrocortisone, Leucovorin, Dexamethasone, Vincristine, Doxorubicin, Dexrazoxane, Calaspargase Pegol, Erwinia asparaginase; Drug
Lead sponsor: Andrew E. Place, MD; Other
Eligibility: 1 Year to 40 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 5
States / cities: San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 2 more

Conditions: Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Stage IV Breast Cancer
Interventions: Nab-Paclitaxel, Paclitaxel, Docetaxel, Phesgo, T-DM1, Pertuzumab, Trastuzumab Deruxtecan, Trastuzumab Subcutaneous Subcutaneous, Tucatinib, Trastuzumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infection
Interventions: ritonavir, fosamprenavir; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 13 more

Conditions: Bloating
Interventions: Hypnotherapy; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Atopic Dermatitis
Interventions: Abrocitinib; Drug
Lead sponsor: Innovaderm Research Inc.; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 6
States / cities: Birmingham, Alabama • Fountain Valley, California • Miami Lakes, Florida + 3 more

Conditions: Cardiovascular Diseases
Interventions: Lipitor 20Mg Tablet, Lipitor 80Mg Tablet, Placebo, Exercise Program; Drug · Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 35 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis, Gout, Arthritis, Joint Pain
Interventions: Dapansutrile, Placebo Tablet; Drug · Other
Lead sponsor: Olatec Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 25
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 21 more

Conditions: Neoplasms, Breast Neoplasms
Interventions: Xentuzumab, Abemaciclib, Letrozole, Anastrozole, Fulvestrant; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 6
States / cities: Santa Monica, California • New Haven, Connecticut • Miami, Florida + 3 more

Conditions: GI Symptoms
Interventions: Hypnotherapy, Educational module; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
Interventions: Brexpiprazole, OPC-34712, Placebo Oral Tablet; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 37
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Bellflower, California + 25 more

Conditions: Borderline Personality Disorder
Interventions: Brexpiprazole, Placebo; Drug · Other
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 66
States / cities: Bentonville, Arkansas • Bellflower, California • Beverly Hills, California + 56 more

Conditions: Crohn Disease, CARD9 S12N Risk Allele
Interventions: Posaconazole Delayed Release Oral Tablet, Matching Placebo Tablet; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Los Angeles, California • Rochester, Minnesota

Conditions: Melanoma
Interventions: In-person counseling, Workbook, Tablet Computer-Based Education; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Infections
Interventions: Cabotegravir Tablets, Cabotegravir Injectable Suspension (CAB LA), Rilpivirine Tablets, Rilpivirine Injectable Suspension (RPV LA), BIKTARVY Tablets (BIK); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 687 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 41
States / cities: Bakersfield, California • Beverly Hills, California • Los Angeles, California + 32 more

Conditions: Schizophrenia, Bipolar I Disorder
Interventions: VHX-896 and iloperidone, Iloperidone and VHX-896; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 3
States / cities: Los Alamitos, California • Gaithersburg, Maryland • Marlton, New Jersey

Search by objective public record fields.

Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery Disease

The Effect of Combinatorial Nutritional Supplementation on Immune Function in Healthy Older Adults

A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Tadalafil Taken Daily Compared to Placebo on Improvement of Getting and Maintaining an Erection and Sexual Quality of Life

Chronic Stroke Rehabilitation With Contralesional Brain-Computer Interface

LiveSMART Trial to Prevent Falls in Patients With Cirrhosis

Hormone Replacement for Premature Ovarian Insufficiency

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Venetoclax Basket Trial for High Risk Hematologic Malignancies

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years

Treatment of Symptomatic Bloating Using a Novel Hypnotherapy Protocol

Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab

Impact of Statin Therapy on Adaptations to Aerobic Exercise

Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

Treatment of Upper Gastrointestinal Symptoms Using Hypnotherapy Sessions

A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation

A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder

Pilot Study of Posaconazole in Crohn's Disease

A Comparison of Interventions to Teach Melanoma Patients Skin Self-examination

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions